Novo Nordisk shares staged a dramatic rebound on Monday, recovering 8% after a steep 20% plunge on Friday. The recovery was sparked by investor reassessment of the company’s potential following disappointing trial results for its CagriSema weight-loss drug. The broader European markets also saw moderate gains as the pan-European Stoxx…
Rumble Inc (NASDAQ: RUM) opened a whopping 50% up this morning after announcing to have received a $775 million…
Despite the looming uncertainty of President-elect Donald Trump’s trade and tax policies, Wall Street is largely aligning with the…
Shares of Traws Pharma Inc (NASDAQ: TRAW) more than tripled today after reporting encouraging early-stage data for its tivoxavir…
Luigi Mangione, the 26-year-old accused of killing UnitedHealth CEO Brian Thompson, has pleaded not guilty to murder and terrorism…
New home sales in the United States experienced a notable rebound in November, recovering from a downturn caused by…
Tilray Inc (NASDAQ: TLRY) chief executive Irwin Simon expects the recreational use of cannabis to be legalised on a…
President Joe Biden faces a critical decision on Nippon Steel’s $15 billion bid to acquire US Steel, a deal…
Brazil wraps up 2024 in a puzzling duality: impressive economic growth on the one hand and lackluster market performance…